

This is a published notice on the Find a Tender service: <https://www.find-tender.service.gov.uk/Notice/024806-2021>

Planning

## **Call for information/EOI for neutralising antibodies.**

Department of Health and Social Care

F01: Prior information notice

Prior information only

Notice identifier: 2021/S 000-024806

Procurement identifier (OCID): ocids-h6vhtk-02e853

Published 5 October 2021, 4:37pm

### **Section I: Contracting authority**

#### **I.1) Name and addresses**

Department of Health and Social Care

39 Victoria Street

London

SW1H 0EU

#### **Contact**

Amjad Kazmi

#### **Email**

[amjad.kazmi@dhsc.gov.uk](mailto:amjad.kazmi@dhsc.gov.uk)

#### **Country**

United Kingdom

#### **NUTS code**

UKI32 - Westminster

**Internet address(es)**

Main address

<https://www.gov.uk/government/organisations/department-of-health-and-social-care>

Buyer's address

<https://www.gov.uk/government/organisations/department-of-health-and-social-care>

**I.3) Communication**

Additional information can be obtained from the above-mentioned address

Electronic communication requires the use of tools and devices that are not generally available. Unrestricted and full direct access to these tools and devices is possible, free of charge, at

<http://health.atamis.co.uk>

**I.4) Type of the contracting authority**

Ministry or any other national or federal authority

**I.5) Main activity**

Health

---

## Section II: Object

### II.1) Scope of the procurement

#### II.1.1) Title

Call for information/EOI for neutralising antibodies.

#### II.1.2) Main CPV code

- 33600000 - Pharmaceutical products

#### II.1.3) Type of contract

Supplies

#### II.1.4) Short description

DHSC invites suppliers to submit an EOI on neutralising antibodies and binding site, clinical trials on efficacy, safety for preventing or treating COVID-19 infection, dose & frequency, formats/routes for administering to patients, monitoring adverse effects, efficacy against SARS-CoV-2 variants, supply availability for 2021-2022 and future years and plans for regulatory approval in the UK, if not yet approved.

#### II.1.5) Estimated total value

Value excluding VAT: £1

#### II.1.6) Information about lots

This contract is divided into lots: No

### II.2) Description

#### II.2.3) Place of performance

NUTS codes

- UK - United Kingdom

#### II.2.4) Description of the procurement

The Department is interested in engaging with the emerging market through expressions of interest prior to the publication of a contract notice to find innovative neutralising antibody COVID-19 therapies that could inform the specification of requirements, conditions of contract and commercial model. Further details of how

suppliers may engage with the Department are included in section VI.3) (additional information) at the end of this notice.

#### **II.2.14) Additional information**

Interested parties should submit questions via Atamis. Department welcomes discussions with interested parties on areas provision of a value for money solution for the UK tax payer; creating mechanisms for money solution for the UK tax payer; creating mechanisms (including but not limited to agreements) to secure long-term, guaranteed supply contracts with 'step-in' rights in future pandemics

#### **II.3) Estimated date of publication of contract notice**

31 March 2022

---

### **Section IV. Procedure**

#### **IV.1) Description**

##### **IV.1.8) Information about the Government Procurement Agreement (GPA)**

The procurement is covered by the Government Procurement Agreement: Yes

---

### **Section VI. Complementary information**

#### **VI.3) Additional information**

This Prior Information Notice has been issued to alert the market for the possible procurement of neutralising antibodies. Suppliers should submit expressions of interest.